| Product Name | Anti-GFAP Monoclonal Antibody |
|---|---|
| Description | Glial Fibrillary Acidic Protein (GFAP) was discovered by Bignami et al. (1972) as a major fibrous protein of multiple sclerosis plaques. It was subsequently found to be a member of the 10 nm or intermediate filament protein family, specifically the intermediate filament protein family Class III, which also includes peripherin, desmin and vimentin. GFAP is heavily, and specifically, expressed in astrocytes and certain other astroglia in the central nervous system, in satellite cells in peripheral ganglia, and in non-myelinating Schwann cells in peripheral nerves. In addition, neural stem cells frequently strongly express GFAP. It is also found in the lens epithelium, Kupffer cells of the liver, in some cells in salivary tumors and has been reported in erythrocytes. Although its function is not fully understood, GFAP protein is probably involved in controlling the shape and movement of astrocytes. The protein probably also plays a significant role in the interactions of astrocytes with other cells, which are required for the formation and maintenance of the insulating layer (myelin) that covers nerve cells. Additionally, GFAP protein may assist in maintaining the protective barrier that allows only certain substances to pass between blood vessels and the brain (blood-brain barrier).In adults, GFAP levels increase as a result of the proliferation of astrocytes that occurs in a response to a variety of physical, chemical and etiological insults, including Alzheimer’s disease, epilepsy and multiple sclerosis.Antibodies to GFAP are therefore very useful as markers of astrocytic cells and neural stem cells and for distinguishing of neoplasms of astrocytic origin from other neoplasms in the central nervous system. Finally, Alexander's disease was recently shown to be caused by point mutations in protein coding region of the GFAP gene (Brenner et al., 2001). All forms of Alexander disease are characterized by the presence of Rosenthal fibers, which are GFAP containing cytoplasmic inclusions found in astrocytes. |
| Clone | GA-5 |
| Immunogen | Porcine spinal cord |
| Isotype | IgG1 |
| Specificity |
The antibody GA-5 reacts with GFAP, the principal marker of astroglial cells in the central nervous system, which is specifically expressed in satellite cells in peripheral ganglia and in non myelinating Schwann cells in peripheral nerves. The GFAP protein runs on gels at ~55 kDa protein, usually associated with lower Mw bands which are thought to be proteolytic fragments and alternate transcripts from the single gene. |
| Reactivity | Human, Porcine, Rat |
| Applications | ICC, IHC, IP, WB |
| Form | Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4 |
| Storage | Store at 2-8°C. Do not freeze. |
| Background | Glial Fibrillary Acidic Protein (GFAP) was discovered by Bignami et al. (1972) as a major fibrous protein of multiple sclerosis plaques. It was subsequently found to be a member of the 10 nm or intermediate filament protein family, specifically the intermediate filament protein family Class III, which also includes peripherin, desmin and vimentin. GFAP is heavily, and specifically, expressed in astrocytes and certain other astroglia in the central nervous system, in satellite cells in peripheral ganglia, and in non-myelinating Schwann cells in peripheral nerves. In addition, neural stem cells frequently strongly express GFAP. It is also found in the lens epithelium, Kupffer cells of the liver, in some cells in salivary tumors and has been reported in erythrocytes. Although its function is not fully understood, GFAP protein is probably involved in controlling the shape and movement of astrocytes. The protein probably also plays a significant role in the interactions of astrocytes with other cells, which are required for the formation and maintenance of the insulating layer (myelin) that covers nerve cells. Additionally, GFAP protein may assist in maintaining the protective barrier that allows only certain substances to pass between blood vessels and the brain (blood-brain barrier).In adults, GFAP levels increase as a result of the proliferation of astrocytes that occurs in a response to a variety of physical, chemical and etiological insults, including Alzheimer’s disease, epilepsy and multiple sclerosis.Antibodies to GFAP are therefore very useful as markers of astrocytic cells and neural stem cells and for distinguishing of neoplasms of astrocytic origin from other neoplasms in the central nervous system. Finally, Alexander's disease was recently shown to be caused by point mutations in protein coding region of the GFAP gene (Brenner et al., 2001). All forms of Alexander disease are characterized by the presence of Rosenthal fibers, which are GFAP containing cytoplasmic inclusions found in astrocytes. |
| Supplier | Exbio |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
